Literature DB >> 15142877

Multiple patients with revertant mosaicism in a single Wiskott-Aldrich syndrome family.

Taizo Wada1, Shepherd H Schurman, G Jayashree Jagadeesh, Elizabeth K Garabedian, David L Nelson, Fabio Candotti.   

Abstract

We previously reported on a 43-year-old patient with Wiskott-Aldrich syndrome (WAS) who experienced progressive clinical improvement and revertant T-cell mosaicism. Deletion of the disease-causing 6-bp insertion was hypothesized to have occurred by DNA polymerase slippage. We now describe 2 additional patients from the same family who also had revertant T lymphocytes that showed selective in vivo advantage. Somatic mosaicism was demonstrated on leukocytes cryopreserved in the first patient when he was 22 years old, 11 years before his death from kidney failure. The second patient is now 16 years old, has a moderate clinical phenotype, and developed revertant cells after the age of 14 years. These results support DNA polymerase slippage as a common underlying mechanism, and they indicate that T-cell mosaicism may have different clinical effects in WAS.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15142877     DOI: 10.1182/blood-2004-03-0846

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

Review 1.  Revertant mosaicism in skin: natural gene therapy.

Authors:  Joey E Lai-Cheong; John A McGrath; Jouni Uitto
Journal:  Trends Mol Med       Date:  2010-12-29       Impact factor: 11.951

2.  WASP confers selective advantage for specific hematopoietic cell populations and serves a unique role in marginal zone B-cell homeostasis and function.

Authors:  Lisa S Westerberg; Miguel A de la Fuente; Fredrik Wermeling; Hans D Ochs; Mikael C I Karlsson; Scott B Snapper; Luigi D Notarangelo
Journal:  Blood       Date:  2008-09-04       Impact factor: 22.113

Review 3.  Human hyper-IgE syndrome: singular or plural?

Authors:  Qian Zhang; Bertrand Boisson; Vivien Béziat; Anne Puel; Jean-Laurent Casanova
Journal:  Mamm Genome       Date:  2018-08-09       Impact factor: 2.957

4.  Wiskott-Aldrich syndrome protein is required for regulatory T cell homeostasis.

Authors:  Stephanie Humblet-Baron; Blythe Sather; Stephanie Anover; Shirly Becker-Herman; Debora J Kasprowicz; Socheath Khim; Thuc Nguyen; Kelly Hudkins-Loya; Charles E Alpers; Steve F Ziegler; Hans Ochs; Troy Torgerson; Daniel J Campbell; David J Rawlings
Journal:  J Clin Invest       Date:  2007-01-11       Impact factor: 14.808

5.  Multiple correcting COL17A1 mutations in patients with revertant mosaicism of epidermolysis bullosa.

Authors:  Anna M G Pasmooij; Hendri H Pas; Franciska C L Deviaene; Miranda Nijenhuis; Marcel F Jonkman
Journal:  Am J Hum Genet       Date:  2005-09-09       Impact factor: 11.025

Review 6.  Novel molecular therapies for heritable skin disorders.

Authors:  Jouni Uitto; Angela M Christiano; W H Irwin McLean; John A McGrath
Journal:  J Invest Dermatol       Date:  2011-12-08       Impact factor: 8.551

Review 7.  Gene transfer into hematopoietic stem cells as treatment for primary immunodeficiency diseases.

Authors:  Fabio Candotti
Journal:  Int J Hematol       Date:  2014-02-01       Impact factor: 2.490

8.  Wiskott-Aldrich syndrome protein is required for homeostasis and function of invariant NKT cells.

Authors:  Alexander Astrakhan; Hans D Ochs; David J Rawlings
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

9.  Unprecedented diversity of genotypic revertants in lymphocytes of a patient with Wiskott-Aldrich syndrome.

Authors:  Brian R Davis; Michael J Dicola; Nicole L Prokopishyn; Jonathan B Rosenberg; Daniele Moratto; Linda M Muul; Fabio Candotti; R Michael Blaese
Journal:  Blood       Date:  2008-03-10       Impact factor: 22.113

10.  The phenomenon of spontaneous genetic reversions in the Wiskott-Aldrich syndrome: a report of the workshop of the ESID Genetics Working Party at the XIIth Meeting of the European Society for Immunodeficiencies (ESID). Budapest, Hungary October 4-7, 2006.

Authors:  Donn M Stewart; Fabio Candotti; David L Nelson
Journal:  J Clin Immunol       Date:  2007-08-10       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.